Market closedNon-fractional
Generation Bio/GBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Generation Bio
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Ticker
GBIO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
174
Website
generationbio.com
Generation Bio Metrics
BasicAdvanced
$144M
Market cap
-
P/E ratio
-$2.56
EPS
2.87
Beta
-
Dividend rate
Price and volume
Market cap
$144M
Beta
2.87
Financial strength
Current ratio
8.013
Quick ratio
7.746
Long term debt to equity
66.351
Total debt to equity
72.691
Management effectiveness
Return on assets (TTM)
-21.68%
Return on equity (TTM)
-82.24%
Valuation
Price to revenue (TTM)
14.316
Price to book
1.08
Price to tangible book (TTM)
1.08
Price to free cash flow (TTM)
-2.183
Growth
Earnings per share change (TTM)
12.80%
3-year earnings per share growth
4.80%
What the Analysts think about Generation Bio
Analyst Ratings
Majority rating from 7 analysts.
Generation Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$4M
42.86%
Net income
-$75M
112.25%
Profit margin
-1,862.50%
48.58%
Generation Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.43
-$0.53
-$1.12
-
Expected
-$0.50
-$0.51
-$0.45
-$0.41
-$0.28
Surprise
-5.40%
-14.85%
18.15%
174.41%
-
Generation Bio News
AllArticlesVideos
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
GlobeNewsWire·3 weeks ago
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Generation Bio stock?
Generation Bio (GBIO) has a market cap of $144M as of July 06, 2024.
What is the P/E ratio for Generation Bio stock?
The price to earnings (P/E) ratio for Generation Bio (GBIO) stock is 0 as of July 06, 2024.
Does Generation Bio stock pay dividends?
No, Generation Bio (GBIO) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Generation Bio dividend payment date?
Generation Bio (GBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Generation Bio?
Generation Bio (GBIO) has a beta rating of 2.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Generation Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.